In silico analysis identifies CRISP3 as a potential peripheral blood biomarker for multiple myeloma: From data modeling to validation with RT-PCR.

Octamer-binding protein 2 (Oct2) binds to the ATGCAAAT octamer on the IgH enhancer and stimulates IgH expression in human multiple myeloma (MM). Cysteine-rich secreted protein 3 (CRISP3) possesses the ATGCAAAT sequence and thus is activated by Oct2 in mouse B cells, suggesting that CRISP3 may be activated in and be a potential biomarker for MM. The present study involved a meta-analysis of the gene expression profiling data of human MM peripheral blood. Significantly expressed genes were analyzed on merged super array microarray data and selected sample data with significantly expressed genes were additionally analyzed by principal component analysis and Bayesian probit regression. CRISP3, Oct2, Apha-1B-glycoprotein (A1GB) and Cyclin D2 (CCND2) were validated in clinical MM peripheral blood samples using reverse transcription quantitative polymerase chain reaction. In the gene expression profiling data, CRISP3 was significantly upregulated and had certain proportions on the discriminated principal component of significantly expressed gene sample data. RT-qPCR analysis revealed CRISP3 was significantly upregulated in MM. Therefore, CRISP3 is a potential peripheral blood biomarker for MM.